Cannabis
The Valens Company Secures DTC Eligibility
Valens GroWorks Corp (TSXV: VLNS) (OTCQX: VLNCF) (the “Company“, “Valens” or “The Valens Company“), a vertically integrated provider of industry-leading extraction products and services; including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab, is pleased to announce that it has obtained eligibility from the Depositary Trust Company (“DTC”) for its shares traded on the OTCQX, under the symbol “VLNCF.”
“Executing on our milestone of obtaining DTC eligibility demonstrates Valens’ commitment to increased visibility and accessibility for shareholders moving into fiscal 2020,” said Tyler Robson, CEO of The Valens Company. “Access to DTC’s platform not only brings us closer to increasing trading volume and liquidity in the United States, but also allows us to reach new investors in larger markets who now can invest in our evolving business.”
The DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers while cutting costs and providing access to a wider network of brokerage firms. DTC is a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the U.S. Securities and Exchange Commission.
SOURCE Valens GroWorks Corp.
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis5 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE6 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis5 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Humboldt5 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis3 days ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III